Summary
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
History
Seelos was founded in 2017, and is led by a highly experienced management team. They have a broad pipeline of medications in various stages of development, with a focus on diseases that have significant unmet medical needs. Seelos has raised more than $80M in equity capital, and leveraged partnerships, to advance its clinical development programs.
Mission
Our mission at Seelos is to provide safe, effective, and affordable treatments for a wide range of central nervous system disorders, orphan diseases, and other unmet medical needs.
Vision
Seelos is committed to making meaningful differences in the lives of individuals living with CNS and rare diseases. We envision a future in which more people will achieve optimal medical outcomes, while avoiding the stress and discomfort of treatments that are too expensive or not available.
Key Team
Mr. Anthony Marciano (Chief Communications Officer)
Ms. Karen Fusaro (Sr. VP & Head of Clinical Operations)
Gopal Krishna Ph.D. (Head of Manufacturing & Technical Operations)
Tim Whitaker M.D. (Chief Medical Officer)
Recognition and Awards
Seelos has been recognized by various organizations and publications for its commitment to patient advocacy, scientific innovation, and industry leadership. In April 2019, we were presented with the Community Advocate Award from ESRD Network 8 for our work on chronic kidney disease. We have also been recognized in Forbes Magazine, Gilead Magazine, and the 2018 Innotech Conference.
References
United States 